Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation
暂无分享,去创建一个
W. Powderly | K. Mayer | P. Chan | C. Mejía | Amy C. Nunn | Jingxia Liu | R. Patel | J. Meléndez | I. Ross | Katherine E. Goodenberger
[1] R. Gandhi. Preexposure Prophylaxis for the Prevention of HIV , 2018 .
[2] Ashley J. Mayo,et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. , 2016, The New England journal of medicine.
[3] Jennifer F Hoy,et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. , 2016, JAMA.
[4] A. van der Straten,et al. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa , 2016, PloS one.
[5] Sheena McCormack,et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.
[6] M. Mimiaga,et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities , 2016, Journal of the International AIDS Society.
[7] N. Kilonzo,et al. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation , 2016, Current opinion in HIV and AIDS.
[8] David Thompson,et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.
[9] Venkatesan Chakrapani,et al. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation. , 2015, AIDS patient care and STDs.
[10] J. Auerbach,et al. Beyond “getting drugs into bodies”: social science perspectives on pre-exposure prophylaxis for HIV , 2015, Journal of the International AIDS Society.
[11] R. Macklin,et al. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access , 2015, Journal of the International AIDS Society.
[12] W. Heneine,et al. Cabotegravir long-acting for HIV-1 prevention , 2015, Current opinion in HIV and AIDS.
[13] K. Mayer,et al. PrEP implementation: moving from trials to policy and practice , 2015, Journal of the International AIDS Society.
[14] Frederick Albert Matsen IV,et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. , 2015, The Journal of infectious diseases.
[15] J. Baeten,et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. , 2015, JAMA internal medicine.
[16] R. Baggaley,et al. Young key populations and HIV: a special emphasis and consideration in the new WHO Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations , 2015, Journal of the International AIDS Society.
[17] Megha L Mehrotra,et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. , 2014, The Lancet. Infectious diseases.
[18] David R. Holtgrave,et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.
[19] K. Mayer,et al. HIV Providers’ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study , 2014, AIDS and Behavior.
[20] Megha L Mehrotra,et al. HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial , 2014, The Journal of infectious diseases.
[21] P. Polgreen,et al. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] M. Mimiaga,et al. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts , 2014, AIDS care.
[23] J. Lama,et al. Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. , 2014, AIDS research and human retroviruses.
[24] D. Glidden,et al. No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis , 2013, PloS one.
[25] David M. Tellalian,et al. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. , 2013, AIDS patient care and STDs.
[26] L. Grohskopf,et al. Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States , 2013, Journal of acquired immune deficiency syndromes.
[27] C. Hendrix,et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.
[28] G. Ippolito,et al. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists , 2013, BMC Infectious Diseases.
[29] Ashley A. Eggman,et al. Cost–effectiveness of pre-exposure prophylaxis for HIV: a review , 2012, Current opinion in HIV and AIDS.
[30] K. Mayer,et al. Engaging healthcare providers to implement HIV pre-exposure prophylaxis , 2012, Current opinion in HIV and AIDS.
[31] John T Brooks,et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.
[32] James D. Campbell,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.
[33] Katrien Fransen,et al. Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.
[34] M. Mimiaga,et al. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. , 2012, AIDS patient care and STDs.
[35] W. Duffus,et al. Preexposure Prophylaxis for HIV Infection: Healthcare Providers’ Knowledge, Perception, and Willingness to Adopt Future Implementation in the Southern US , 2012, Southern medical journal.
[36] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.
[37] J. Baeten,et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. , 2008, The Journal of infectious diseases.
[38] K. Holmes,et al. Sentinel Surveillance of Sexually Transmitted Infections/HIV and Risk Behaviors in Vulnerable Populations in 5 Central American Countries , 2007, Journal of acquired immune deficiency syndromes.
[39] D. Fleming,et al. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. , 1999, Sexually transmitted infections.